Find Your Board CEU Requirements & Accreditations:
Return to Course List

Daclatasvir, Elbasvir, and Grazoprevir in the Treatment of Chronic Hepatitis C - New Hepatitis C Virus Therapies

Author: Noah H. Carpenter, MD

CE: 2.5 hours Pharmacology: 2.5 hours
Rated 4.8 out of 5.0 based on 545 reviews

Course Summary

Hepatitis C virus can cause acute and chronic liver disease. The primary treatment of chronic hepatitis C is antiviral therapy. New antiviral therapy can generally eradicate the virus through an easier and shorter course of care than with prior methods and offer a different approach — targeting the virus itself to fight off the disease — that is proving successful in the fight against hepatitis C. An important consideration for patients diagnosed with chronic hepatitis C viral infection includes ongoing surveillance for liver fibrosis and other complications that can lead to significant morbidity and mortality. This is the fourth in a five course series on Hepatitis C.

Course Format


Course Syllabus

I.              Treating Hepatitis C with Daclatasvir

1.   Side Effects

2.   HCV Life Cycle

3.   Co-infection and Daclatasvir

4.   Dosing and Duration of Treatment

II.           Daclatasvir and Treatment Response

1.   Drug Interactions and Warnings

2.   Cost of Therapy

III.         Elbasvir and Grazoprevir

1.   Resistant Viruses

2.   Adverse Effects

3.   Drug Precaution and Warning

4.   Goal of Therapy

5.   Additional Considerations

6.   Cost of Therapy

IV.          Case Study

1.   Discussion.

V.            Summary


Most of our courses will satisfy your CEU requirements. However, you can double check by using the search option at the top of this page.
You can download all the required materials above where it says "Preview the material"
No prerequisites are required for this course.
Yes. Once you read the material and complete the evaluation you can print your certificate right away from your "My Account" page.

How it Works


1. Confirm Your


2. Read the


4. Print Your